Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759115 | 0.92 | HSD11B1 (0.61) | HSD11B1CYP2D6NPY5RSIGMAR1HRH3 | |
| SCHEMBL4759117 | 0.92 | HSD11B1 (0.61) | HSD11B1CYP2D6NPY5RSIGMAR1HRH3 | |
| SCHEMBL6080148 | 0.80 | HSD11B1 (0.54) | HSD11B1CYP2D6NPY5RSIGMAR1HRH3 | |
| SCHEMBL4757016 | 0.79 | HSD11B1 (0.51) | HSD11B1CYP2D6NPY5RSIGMAR1HRH3 | |
| SCHEMBL4755631 | 0.79 | HSD11B1 (0.51) | HSD11B1CYP2D6NPY5RSIGMAR1HRH3 | |
| SCHEMBL3687620 | 0.78 | HSD11B1 (0.62) | HSD11B1CYP2D6NPY5RSIGMAR1 | |
| SCHEMBL6080181 | 0.77 | HSD11B1 (0.51) | HSD11B1CYP2D6NPY5RHRH3 | |
| SCHEMBL4757345 | 0.77 | HSD11B1 (0.64) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL4757352 | 0.77 | HSD11B1 (0.64) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL349129 | 0.77 | HSD11B1 (0.55) | HSD11B1CYP2D6NPY5RSIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | claimed |
| EP-1758582-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1758582-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.